As per the terms of the agreement, Pharming is entitled to receive certain commercial, regulatory and clinical milestones from MegaPharm.
MegaPharm will buy its commercial supply of Ruconest from Pharming at a supply price, based on a percentage of net sales of Ruconest.
MegaPharm expects to launch Ruconest in 2012.
Pharming CEO Sijmen de Vries they are pleased to have taken a another step towards making Ruconest available to HAE patients globally.